Quotes 5-day view Delayed Japan Exchange
08/04/2022
08/05/2022
08/08/2022
08/09/2022
08/10/2022
Date
1091(c)
1110(c)
1120(c)
1087(c)
1107
Last
1 016 700
1 093 200
1 093 100
1 103 200
753 300
Volume
+1.77%
+1.74%
+0.90%
-2.95%
+1.84%
Change
Estimated financial data (e) JPY USD
Sales 2023
549 B
4 070 M
4 070 M
Net income 2023
25 250 M
187 M
187 M
Net Debt 2023
48 352 M
358 M
358 M
P/E ratio 2023
15,0x
Yield 2023
2,58%
Sales 2024
407 B
3 019 M
3 019 M
Net income 2024
-34 417 M
-255 M
-255 M
Net Debt 2024
18 748 M
139 M
139 M
P/E ratio 2024
-12,7x
Yield 2024
2,48%
Capitalization
432 B
3 200 M
3 200 M
EV / Sales 2023
0,87x
EV / Sales 2024
1,11x
Nbr of Employees
6 987
Free-Float
40,8%
Sumitomo Dainippon Pharma Co., Ltd. specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceuticals (92.8%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment;
- other (7.2%): veterinary drugs, food additives, industrial chemical products, etc.
Net...
Ratings of Sumitomo Dainippon Pharma Co., Ltd.
All news about SUMITOMO DAINIPPON PHARMA CO., LTD.
08/09 Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and.. AQ
08/08 Sumitomo Pharma Co., Ltd. - Myovant Sciences and Pfizer Receive U.S. FDA Approval of MY.. AQ
08/05 SUMITOMO DAINIPPON PHARMA : Jul. 29, 2022 Q1 FY2022 Conference Call transcript (PDF/1,785K..PU
08/03 Sumitomo Pharma Co., Ltd. and Eli Lilly Japan K.K. Announces Conclusion of Sales Collab.. CI
08/02 SUMITOMO DAINIPPON PHARMA : Notice of conclusion of sales collaboration for GLP-1 receptor..PU
08/01 Nikkei 225 Up 0.7% on Earnings, Wall Street Cues MT
08/01 Japanese shares jump most in nearly two weeks on positive earnings RE
07/31 Japanese shares edge higher with focus on earnings, global growth RE
07/29 TRANSCRIPT : Sumitomo Pharma Co., Ltd., Q1 2023 Earnings Call, Jul 29, 2022CI
07/29 SUMITOMO DAINIPPON PHARMA : Summary of Consolidated Financial Results for the First Quarte..PU
07/29 SUMITOMO DAINIPPON PHARMA : Notice Concerning Finance IncomePU
07/29 SUMITOMO DAINIPPON PHARMA : Supplementary Financial Data (IFRS) for the First Quarter of t..PU
07/29 SUMITOMO DAINIPPON PHARMA : Q1 FY2022 (April 1 to June 30, 2022) Conference CallPU
07/29 Sumitomo Pharma Co., Ltd. Provides Earnings Guidance for the Year Ending March 31, 2023 CI
07/29 Sumitomo Pharma Co., Ltd. Provides Second Quarter and Year End Dividend Guidance for th.. CI
News in other languages on SUMITOMO DAINIPPON PHARMA CO., LTD.
Chart SUMITOMO DAINIPPON PHARMA CO., LTD.
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends SUMITOMO DAINIPPON PHARMA CO., LTD.
Short Term Mid-Term Long Term Trends Neutral Bearish Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
1 087,00 JPY
Average target price
1 015,00 JPY
Spread / Average Target
-6,62%
Please enable JavaScript in your browser's settings to use dynamic charts.